No title
Monoclonal antibody (mAb) fragments have become the formats of choice for both biopharmaceuticals and ligands in analytical and preparative applications. Their smaller size enables additional advantages over full-length mAbs, such as improved tissue penetration, faster blood clearance for diagnostic applications, improved capacity, and enablement of multivalent formatting. However, limitations in
